Skip to content

Preliminary clinical evaluation of Hibiscus sabdariffa L.calyx on treatment of dyslipidemia in adolescents

Clinical evaluation of Hibiscus sabdariffa L. in comparision with placebo on treatment of dyslipidemia in adolescents between 12-18 years old

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201109122306N2
Enrollment
72
Registered
2011-12-28
Start date
2011-05-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia. Hyperlipidaemia,unspecified

Interventions

Intervention 1: Hibiscus sabdariffa L. calices powdered and packed in 2 gr sachets. Each patient consumed 3 sachets per day during one month. Intervention 2: Placebo powder packed in 2 gr sachets and
Treatment - Drugs
Placebo
Hibiscus sabdariffa L. calices powdered and packed in 2 gr sachets. Each patient consumed 3 sachets per day during one month.
Placebo powder packed in 2 gr sachets and each patient consumed 3 sachets per day during one month.

Sponsors

Vice chancellor for research, Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1)adolescents between 12 to 18 years old that have at least one of these criteria: a: triglyceride more than 90 percentile b: total cholesterol more than 90 percentile c: LDL more than 90 percentile d:HDL less than 10 percentile 2) Not using tobacco 3) No history of alcohol consumption or drug abuse 4) No history of metabolic diseases like diabetes, thyroid gland dysfunction, nephrotic syndrome, chronic pancreatitis, liver and gall bladder diseases that affects lipid profiles 5) Not using drugs which affect lipid profiles like statins and hormonal pills like estrogens, progestrones and oral contraceptives. Exclusion criteria: 1) Lack of patient’s compliance with drug regimens at least for one week. 2) Pregnancy and lactation 3) Drug sensitivity 4) Suffering from any diseases which interact with lipid profiles 5) Intake of any kind of drugs or other compounds lowering lipid profile like corticosteroids, androgens, estrogenes, progestines, thiazides, beta blockers and thyroid hormones

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
LDL Cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;HDL Cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;Triglyceride. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;Total cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Ataei

Isfahan University of Medical Sciences

ataei_ehsan109@yahoo.com+98 31 1778 2798

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 24, 2026